LeMaitre Vascular’s (LMAT) Outperform Rating Reiterated at Barrington Research

Barrington Research restated their outperform rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research note released on Friday,Benzinga reports. The brokerage currently has a $95.00 target price on the medical instruments supplier’s stock.

A number of other research analysts have also weighed in on the company. Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, December 6th. Wells Fargo & Company decreased their target price on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th. Roth Mkm reaffirmed a “buy” rating and set a $108.00 price target on shares of LeMaitre Vascular in a research note on Wednesday, November 5th. Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $100.20.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $92.94 on Friday. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44. The stock’s 50 day moving average is $85.54 and its two-hundred day moving average is $88.13. LeMaitre Vascular has a twelve month low of $71.42 and a twelve month high of $105.55. The firm has a market capitalization of $2.11 billion, a PE ratio of 40.06, a P/E/G ratio of 2.06 and a beta of 0.72.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds have recently added to or reduced their stakes in LMAT. Parkside Financial Bank & Trust raised its position in shares of LeMaitre Vascular by 1,913.3% in the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 287 shares during the last quarter. Cornerstone Planning Group LLC grew its stake in LeMaitre Vascular by 534.0% in the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 283 shares during the period. MAI Capital Management purchased a new stake in LeMaitre Vascular in the 3rd quarter worth approximately $38,000. First Horizon Corp acquired a new position in LeMaitre Vascular in the 3rd quarter valued at $39,000. Finally, Geneos Wealth Management Inc. lifted its stake in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 398 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.